<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:37:22 -0700</creation_date>
  <update_date>2013-01-15 20:37:22 -0700</update_date>
  <accession>HMDBP10742</accession>
  <secondary_accessions>
    <accession>17004</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>C-type lectin domain family 5 member B</synonym>
    <synonym>CD161 antigen</synonym>
    <synonym>HNKR-P1a</synonym>
    <synonym>NKR-P1A</synonym>
    <synonym>Natural killer cell surface protein P1A</synonym>
  </synonyms>
  <gene_name>KLRB1</gene_name>
  <general_function>Involved in binding</general_function>
  <specific_function>Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01542</accession>
      <name>N-Acetyllactosamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00790</accession>
      <name>N-Palmitoylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00829</accession>
      <name>N-Stearoylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00831</accession>
      <name>N-Lignoceroylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00950</accession>
      <name>Cer(d18:1/23:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04947</accession>
      <name>Ceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04948</accession>
      <name>Ceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04949</accession>
      <name>Ceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04950</accession>
      <name>Ceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04951</accession>
      <name>Ceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04952</accession>
      <name>Ceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04953</accession>
      <name>Cer(d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04954</accession>
      <name>Cer(d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04955</accession>
      <name>Cer(d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04956</accession>
      <name>Ceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04957</accession>
      <name>Ceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06752</accession>
      <name>Dihydroceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10697</accession>
      <name>Cer(t18:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11758</accession>
      <name>Cer(d18:0/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11759</accession>
      <name>Cer(d18:0/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11760</accession>
      <name>Cer(d18:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11761</accession>
      <name>Cer(d18:0/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11762</accession>
      <name>Cer(d18:0/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11763</accession>
      <name>Cer(d18:0/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11764</accession>
      <name>Cer(d18:0/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11765</accession>
      <name>Cer(d18:0/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11766</accession>
      <name>Cer(d18:0/22:1(13Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11767</accession>
      <name>Cer(d18:0/23:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11768</accession>
      <name>Cer(d18:0/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11769</accession>
      <name>Cer(d18:0/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11770</accession>
      <name>Cer(d18:0/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11771</accession>
      <name>Cer(d18:0/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11772</accession>
      <name>Cer(d18:0/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11773</accession>
      <name>Cer(d18:1/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11774</accession>
      <name>Cer(d18:1/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11775</accession>
      <name>Cer(d18:1/22:1(13Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00024</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00140</accession>
      <name>Glucosylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04832</accession>
      <name>Galabiosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04833</accession>
      <name>Galabiosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04834</accession>
      <name>Galabiosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04835</accession>
      <name>Galabiosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04836</accession>
      <name>Galabiosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04837</accession>
      <name>Galabiosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04838</accession>
      <name>Galabiosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04839</accession>
      <name>Galabiosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04840</accession>
      <name>Galabiosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04841</accession>
      <name>Galabiosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04866</accession>
      <name>Lactosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04872</accession>
      <name>Lactosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04873</accession>
      <name>Lactosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04874</accession>
      <name>Lactosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04876</accession>
      <name>Lactosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04877</accession>
      <name>Trihexosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04878</accession>
      <name>Trihexosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04879</accession>
      <name>Trihexosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04880</accession>
      <name>Trihexosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04881</accession>
      <name>Trihexosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04882</accession>
      <name>Trihexosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04883</accession>
      <name>Trihexosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04884</accession>
      <name>Trihexosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04886</accession>
      <name>Trihexosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04887</accession>
      <name>Trihexosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04958</accession>
      <name>Tetrahexosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04959</accession>
      <name>Tetrahexosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04960</accession>
      <name>Tetrahexosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04961</accession>
      <name>Tetrahexosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04962</accession>
      <name>Tetrahexosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04963</accession>
      <name>Tetrahexosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04964</accession>
      <name>Tetrahexosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04965</accession>
      <name>Tetrahexosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04966</accession>
      <name>Tetrahexosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04967</accession>
      <name>Tetrahexosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04968</accession>
      <name>Tetrahexosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04969</accession>
      <name>Glucosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04970</accession>
      <name>Glucosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04971</accession>
      <name>Glucosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04972</accession>
      <name>Glucosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04973</accession>
      <name>Glucosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04974</accession>
      <name>Glucosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04975</accession>
      <name>Glucosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04976</accession>
      <name>Glucosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04977</accession>
      <name>Glucosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04978</accession>
      <name>Glucosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04979</accession>
      <name>Glucosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06750</accession>
      <name>Lactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10708</accession>
      <name>Galactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10709</accession>
      <name>Galactosylceramide (d18:1/18:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10710</accession>
      <name>Galactosylceramide (d18:1/20:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10711</accession>
      <name>Galactosylceramide (d18:1/22:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10712</accession>
      <name>Galactosylceramide (d18:1/24:1(15Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10713</accession>
      <name>Galactosylceramide (d18:1/26:1(17Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10714</accession>
      <name>Galactosylceramide (d18:1/18:1(9Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB11591</accession>
      <name>Lactosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11592</accession>
      <name>Lactosyceramide (d18:1/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11594</accession>
      <name>Lactosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11595</accession>
      <name>Lactosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12237</accession>
      <name>Inositol-P-ceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12256</accession>
      <name>Mannosyl-diinositol-phosphorylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12257</accession>
      <name>Mannosyl-inositol-phosphorylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12311</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12312</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12313</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12314</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12315</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12316</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12317</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12318</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12319</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12320</accession>
      <name>Galactosylceramide (d18:1/12:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB12321</accession>
      <name>Galactosylceramide (d18:1/14:0) </name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Single-pass type II membrane protein (Potential)</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>12p13</locus>
    <gene_sequence>&gt;677 bp
ATGGACCAACAAGCAATATATGCTGAGTTAAACTTACCCACAGACTCAGGCCCAGAAAGT
TCTTCACCTTCATCTCTTCCTCGGGATGTCTGTCAGGGTTCACCTTGGCATCAATTTGCC
CTGAAACTTAGCTGTGCTGGGATTATTCTCCTTGTCTTGGTTGTTACTGGGTTGAGTGTT
TCAGTGACATCCTTAATACAGAAATCATCAATAGAAAAATGCAGTGTGGACATTCAACAG
AGCAGGAATAAAACAACAGAGAGACCGGGTCTCTTAAACTGCCCAATATATTGGCAGCAA
CTCCGAGAGAAATGCTTGTTATTTTCTCACACTGTCAACCCTTGGAATAACAGTCTAGCT
GATTGTTCCACCAAAGAATCCAGCCTGCTGCTTATTCGAGATAAGGATGAATTGATACAC
ACACAGAACCTGATACGTGACAAAGCAATTCTGTTTTGGATTGGATTAAATTTTTCATTA
TCAGAAAAGAACTGGAAGTGGACAAACGGCTCTTTTTTAAATTCTAATGACTTAGAAATT
AGAGGTGATGCTAAAGAAAACAGCTGTATTTCCATCTCACAGACATCTGTGTATTCTGAG
TACTGTAGTACAGAAATCAGATGGATCTGCCAAAAAGAACTAACACCTGTGAGAAATAAA
GTGTATCCTGACTCTTG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>225</residue_number>
    <molecular_weight>25414.6</molecular_weight>
    <theoretical_pi>6.25</theoretical_pi>
    <pfams>
      <pfam>
        <name>Lectin_C</name>
        <pfam_id>PF00059</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>46-66</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Killer cell lectin-like receptor subfamily B member 1
MDQQAIYAELNLPTDSGPESSSPSSLPRDVCQGSPWHQFALKLSCAGIILLVLVVTGLSV
SVTSLIQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLA
DCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEI
RGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>89941407</genbank_protein_id>
  <uniprot_id>Q12918</uniprot_id>
  <uniprot_name>KLRB1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>BC113997</genbank_gene_id>
  <genecard_id>KLRB1</genecard_id>
  <geneatlas_id>KLRB1</geneatlas_id>
  <hgnc_id>HGNC:6373</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Lanier LL, Chang C, Phillips JH: Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol. 1994 Sep 15;153(6):2417-28.</reference_text>
      <pubmed_id>8077657</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Poggi A, Costa P, Tomasello E, Moretta L: IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation. Eur J Immunol. 1998 May;28(5):1611-6.</reference_text>
      <pubmed_id>9603467</pubmed_id>
    </reference>
    <reference>
      <reference_text>Iiai T, Watanabe H, Suda T, Okamoto H, Abo T, Hatakeyama K: CD161+ T (NT) cells exist predominantly in human intestinal epithelium as well as in liver. Clin Exp Immunol. 2002 Jul;129(1):92-8.</reference_text>
      <pubmed_id>12100027</pubmed_id>
    </reference>
    <reference>
      <reference_text>Aldemir H, Prod'homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, Bihl F, Braud VM: Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor.  J Immunol. 2005 Dec 15;175(12):7791-5.</reference_text>
      <pubmed_id>16339512</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL: Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol. 2005 Dec 15;175(12):7796-9.</reference_text>
      <pubmed_id>16339513</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pozo D, Vales-Gomez M, Mavaddat N, Williamson SC, Chisholm SE, Reyburn H: CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid sphingomyelinase. J Immunol. 2006 Feb 15;176(4):2397-406.</reference_text>
      <pubmed_id>16455998</pubmed_id>
    </reference>
    <reference>
      <reference_text>Christiansen D, Mouhtouris E, Milland J, Zingoni A, Santoni A, Sandrin MS: Recognition of a carbohydrate xenoepitope by human NKRP1A (CD161).  Xenotransplantation. 2006 Sep;13(5):440-6.</reference_text>
      <pubmed_id>16925668</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
  </metabolite_references>
</protein>
